ストックスクリーナーアプリを入手
3.02
0.00%
0.05
アフターアワーズ：
3.03
0.010
+0.33%
前日終値:
$2.97
開ける：
$2.98
24時間の取引高:
48,251
Relative Volume:
0.79
時価総額：
$85.66M
収益：
$709.00K
当期純損益:
$-43.14M
株価収益率:
-0.6652
EPS:
-4.54
ネットキャッシュフロー:
$-20.35M
1週間 パフォーマンス:
-10.54%
1か月 パフォーマンス:
+2.77%
6か月 パフォーマンス:
+21.22%
1年 パフォーマンス:
+8.00%
1日の値動き範囲:
$2.836
$2.995
1週間の範囲:
$2.836
$3.3996
52週間の値動き範囲:
$1.922
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
名前
OncoCyte Corporation
セクター
電話
510-775-0515
住所
1010 Atlantic Avenue, Suite 102, Alameda, CA
OCX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
2.995 | 93.23M | 709.00K | -43.14M | -20.35M | -4.54 |
|
ONC
Beone Medicines Ltd Adr
|
255.57 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.75 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
492.83 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
OncoCyte Corporation (OCX) 最新ニュース
Midday Stock Roundup: GEN Restaurants Down. BJ’s Restaurants Up - Orange County Business Journal
Lake Street Capital Forecasts Strong Price Appreciation for OncoCyte (NASDAQ:OCX) Stock - Defense World
Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OC - GuruFocus
Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OCX Stock News - GuruFocus
Oncocyte (OCX) Gains Favorable Reimbursement for GraftAssureCore Test | OCX Stock News - GuruFocus
OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OC - GuruFocus
OncoCyte reports Medicare boosts reimbursement for GraftAssureCore - TipRanks
OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OCX Stock News - GuruFocus
OncoCyte price target raised to $8 from $5 at Lake Street - TipRanks
Oncocyte Corp Says New CMS Reimbursement Price Rate Of $2,753 Per Result For Graftassurecore Assay - marketscreener.com
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology - The Manila Times
Medicare Approves 24% Higher Payment for Oncocyte's Transplant Test: $1B Market Opportunity Expands - Stock Titan
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology - The Globe and Mail
OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative - MSN
OncoCyte Corp’s Earnings Call: Optimism Amid Challenges - TipRanks
OncoCyte (NASDAQ:OCX) Earns “Buy” Rating from Needham & Company LLC - Defense World
OncoCyte (OCX) Seeks FDA Approval by 2026 - GuruFocus
OncoCyte Corporation (NASDAQ:OCX) Q1 2025 Earnings Call Transcript - Insider Monkey
Needham maintains Buy on OncoCyte, price target at $4.25 - Investing.com Australia
Needham maintains Buy on OncoCyte, price target at $4.25 By Investing.com - Investing.com Nigeria
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ... - Yahoo Finance
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic - GuruFocus
OncoCyte (OCX) Maintains 'Buy' Rating and Price Target by Needha - GuruFocus
Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations By Investing.com - Investing.com Nigeria
OncoCyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations - Investing.com
OncoCyte: Q1 Earnings Snapshot - San Antonio Express-News
OncoCyte Corp (OCX) Q1 2025 Earnings: Revenue Soars to $2.1 Mill - GuruFocus
Oncocyte Reports Q1 2025 Results and Business Progress - The Manila Times
Oncocyte Corp. Reports Q1 2025 Revenue of $2.1 Million and Plans Company Renaming - Nasdaq
Oncocyte Corp SEC 10-Q Report - TradingView
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - The Manila Times
Oncocyte To Release First Quarter 2025 Results On May 12, 2025 - Barchart.com
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX) - Defense World
Oncocyte Provides Positive Update on Clinical Trial Progress | O - GuruFocus
Why Tesla Stock Hit the Brakes Today - The Globe and Mail
AP PHOTOS: US stocks sink after a weak report on the economy - The Globe and Mail
Oncocyte (OCX) Advances Towards Crucial Clinical Trial for Trans - GuruFocus
Oncocyte advances toward clinical trial for transplant test By Investing.com - Investing.com India
Oncocyte advances toward clinical trial for transplant test - Investing.com Australia
Oncocyte Provides Positive Update on Clinical Trial Progress - The Manila Times
Oncocyte Provides Positive Update on Clinical Trial Progress | OCX Stock News - GuruFocus
Oncocyte Provides Positive Update On Clinical Trial ProgresS - marketscreener.com
Leading US Transplant Centers Back Oncocyte's Revolutionary Rejection Test Clinical Trial - Stock Titan
OncoCyte (NASDAQ:OCX) Trading Down 3.1% – Here’s What Happened - Defense World
Oncocyte study links blood test to kidney rejection markers - Investing.com
Economic Uncertainty Weighs on PayPal - The Globe and Mail
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Val - GuruFocus
Oncocyte (OCX) Unveils Promising Data on Transplant Rejection Te - GuruFocus
OncoCyte Corporation (OCX) 財務データ
収益
当期純利益
現金流量
EPS
1.30%
3.35%
大文字化:
|
ボリューム (24 時間):